RAPT
RAPT Therapeutics Inc

2,680
Mkt Cap
$1.01B
Volume
193,602.00
52W High
$42.39
52W Low
$5.67
PE Ratio
-3.31
RAPT Fundamentals
Price
$35.28
Prev Close
$36.62
Open
$36.31
50D MA
$30.02
Beta
1.80
Avg. Volume
394,573.53
EPS (Annual)
-$25.49
P/B
4.06
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Rapt Therapeutics (NASDAQ:RAPT) Sees Strong Trading Volume - Here's Why
Rapt Therapeutics (NASDAQ:RAPT) Sees Unusually-High Trading Volume - Should You Buy...
MarketBeat·14d ago
News Placeholder
More News
News Placeholder
Foresite Capital Management VI LLC Decreases Stock Holdings in Rapt Therapeutics $RAPT
Foresite Capital Management VI LLC decreased its holdings in shares of Rapt Therapeutics (NASDAQ:RAPT - Free Report) by 87.5% in the 2nd quarter, according to its most recent Form 13F filing with the...
MarketBeat·15d ago
News Placeholder
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Rapt Therapeutics (NASDAQ:RAPT) Stock
JPMorgan Chase & Co. boosted their price target on Rapt Therapeutics from $55.00 to $57.00 and gave the company an "overweight" rating in a research note on Wednesday...
MarketBeat·28d ago
News Placeholder
What is HC Wainwright's Estimate for RAPT FY2025 Earnings?
Rapt Therapeutics (NASDAQ:RAPT - Free Report) - Equities researchers at HC Wainwright lifted their FY2025 earnings per share estimates for shares of Rapt Therapeutics in a note issued to investors on...
MarketBeat·1mo ago
News Placeholder
What is Lifesci Capital's Forecast for RAPT FY2025 Earnings?
Rapt Therapeutics (NASDAQ:RAPT - Free Report) - Equities researchers at Lifesci Capital decreased their FY2025 earnings estimates for Rapt Therapeutics in a research report issued to clients and...
MarketBeat·1mo ago
News Placeholder
Rapt Therapeutics (NASDAQ:RAPT) Issues Quarterly Earnings Results
Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.65) earnings per share for the quarter, beating analysts' consensus...
MarketBeat·1mo ago
News Placeholder
Barclays Lowers Rapt Therapeutics (NASDAQ:RAPT) Price Target to $56.00
Barclays reduced their price objective on shares of Rapt Therapeutics from $58.00 to $56.00 and set an "overweight" rating for the company in a research report on Friday...
MarketBeat·1mo ago
News Placeholder
Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 101.02%: Read This Before Placing a Bet
The consensus price target hints at a 101% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·4mo ago
News Placeholder
Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
Zacks·4mo ago
News Placeholder
Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 122.2% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·4mo ago

Latest RAPT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.